The Managing Partner of the law firm Żyglicka i Wspólnicy, attorney-at-law Jarosław Rudy advised the fund Kvarko ASI Sp. z o.o. on its investment in VITROTEST EUROPE Sp. z o.o., a company implementing a R&D project “DEVELOPMENT OF A NEW TYPE OF SYNTHETIC CONTROLS IN IMMUNOENZYMATIC DIAGNOSTIC TESTS USING THE EXAMPLE OF A TEST TO DETECT MEASLES VIRUS INFECTION”.
The total value of funds acquired by VITROTEST EUROPE Sp. z o.o. is PLN 1,000,000.
Vitrotest Europe will design and implement a new type of synthetic controls in ELISA immunoenzymatic diagnostic tests.
ELISA (enzyme-linked immunosorbent assay) is one of the most common tests in biomedical research to detect and quantify proteins contained in the test sample, such as antibodies and antigens. The test is used, among others, in diagnostics for the presence of viruses in human bodies.
The innovation will consist in the introduction of an additional control with low avidity. At present, they are practically unavailable for commercial sale, as they normally require human serum taken from people who are in contact with the pathogen for the first time, which is a deficit in the human population. Vitrotest Europe is developing a new technology that will allow the use of low avidity tests without the need for serum.
The term “avidity” means the resultant of the forces applied between whole antibody molecules and the antigen. Low avidity is characteristic for early infection, which is crucial for the timely implementation of effective treatment (at the beginning of the infection).
In the first stage, a new type of tests will be implemented for the detection of measles virus infection, and then it is planned to extend the scope with further infections.